These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 698569)
1. Drugs for myeloma. Malpas JS; Parker D Br Med J; 1978 Aug; 2(6136):563. PubMed ID: 698569 [No Abstract] [Full Text] [Related]
2. "Protracted pulse" chemotherapy for refractory myeloma: a preliminary report. Manoharan A Eur J Haematol; 1990 Nov; 45(5):274-5. PubMed ID: 2261956 [No Abstract] [Full Text] [Related]
3. Proceedings: Treatment of multiple myeloma by a quadruple chemotherapy regime. Azam L; Delamore IW Br J Haematol; 1974 Jun; 27(2):362. PubMed ID: 4843684 [No Abstract] [Full Text] [Related]
4. Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU. Lee BJ; Sahakian G; Clarkson BD; Krakoff IH Cancer; 1974 Feb; 33(2):533-8. PubMed ID: 4812771 [No Abstract] [Full Text] [Related]
5. VAD followed by VMCP: an alternative regimen for multiple myeloma. Wadhwa J; Kumar L; Kochupillai V Med Oncol; 2002; 19(2):105-8. PubMed ID: 12180477 [TBL] [Abstract][Full Text] [Related]
9. [Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol]. Steinke B; Busch FW; Stapelfeld S; Ostendorf P; Waller HD Dtsch Med Wochenschr; 1984 Jun; 109(26):1015-9. PubMed ID: 6547386 [TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy of multiple myeloma. Review of the recent trials]. Tribalto M; Arcese W; Colombo R; Pastore S; Franchii A Recenti Prog Med; 1981 Aug; 71(2):141-7. PubMed ID: 7031807 [No Abstract] [Full Text] [Related]
11. Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma. Kabir AL; Rahman MJ; Begum M; Dipta TF; Baqui MN; Aziz A; Rahman F; Debnath RC; Habib MA Mymensingh Med J; 2012 Jan; 21(1):114-9. PubMed ID: 22314465 [TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and treatment of generalized plasmacytoma (multiple myeloma)]. Andreeva NE; Antipova LG Ter Arkh; 1977; 49(8):76-85. PubMed ID: 929397 [No Abstract] [Full Text] [Related]
13. Alternating combination chemotherapy does not delay development of refractoriness in myeloma. Osby E; Beksac M; Reizenstein P Anticancer Res; 1986; 6(5):1145-7. PubMed ID: 3800322 [TBL] [Abstract][Full Text] [Related]
14. Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy. Buonanno G; Tortarolo M; Valente A; Castaldo C; Russolillo S; Gonnella F Haematologica; 1978 Feb; 63(1):45-55. PubMed ID: 417971 [No Abstract] [Full Text] [Related]
15. Intensive therapy for myeloma. McElwain TJ; Meldrum M; Gore ME; Millar BC; Malpas JS Pathol Biol (Paris); 1990 Oct; 38(8):830. PubMed ID: 2274375 [No Abstract] [Full Text] [Related]
16. Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study. Alberts DS; Salmon SE Cancer Chemother Rep; 1975; 59(2 Pt 1):345-50. PubMed ID: 1097093 [TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy of multiple bone myeloma. Historical and present day aspects. (Second part) (author's transl)]. Bataille R; Morlock G; Rosenberg F; Sany J; Serre H Sem Hop; 1979 Sep 18-25; 55(31-32):1377-82. PubMed ID: 228415 [TBL] [Abstract][Full Text] [Related]
18. Letter: Treatment of myeloma. Jacobs P; Dubovsky D Br Med J; 1975 Mar; 1(5958):625. PubMed ID: 1125634 [No Abstract] [Full Text] [Related]
19. [Therapy of malignant gammopathies]. Emmerich B Dtsch Med Wochenschr; 1984 Jan; 109(1):26-30. PubMed ID: 6420138 [No Abstract] [Full Text] [Related]
20. The current status and future prospects of treatment for multiple myeloma. Durie BG; Salmon SE Clin Haematol; 1982 Feb; 11(1):181-210. PubMed ID: 6176381 [No Abstract] [Full Text] [Related] [Next] [New Search]